Vaccine Info

TMCP2 Gonorrhea Vaccine


TMCP2 is a vaccine candidate to treat Gonorrhea. It is a complex peptide that is both scalable and economically produced to a high degree of purity.

The candidate elicits bactericidal (killing) antibodies and is efficacious in a preclinical experimental infection model.”

The vaccine formulation also includes an adjuvant to increase the immune response.


TMCP2 is indicated to prevent gonorrhea, a sexually transmitted infection that affects men and women. Untreated, gonorrhea can cause infertility in women.


The vaccine was tested over a range of doses and administration intervals in an animal model. The vaccine elicited a durable and robust immune response, one that significantly reduced both the duration of infection and the level of gonococcal colonization.